Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

134.71USD
15 Jul 2019
Change (% chg)

$0.41 (+0.31%)
Prev Close
$134.30
Open
$135.39
Day's High
$136.30
Day's Low
$134.50
Volume
2,936,750
Avg. Vol
2,008,574
52-wk High
$148.97
52-wk Low
$122.00

Latest Key Developments (Source: Significant Developments)

J&J Denials of Asbestos in Baby Powder Spur Criminal Probe - Bloomberg Law
Friday, 12 Jul 2019 

July 12 (Reuters) - :U.S. DOJ PURSUING CRIMINAL INVESTIGATION INTO WHETHER J&J LIED TO THE PUBLIC ABOUT THE POSSIBLE CANCER RISKS OF ITS TALCUM POWDER- BLOOMBERG LAW.  Full Article

Genmab Announces Submission Of BLA To U.S. FDA For Subcutaneous Formulation Of Daratumumab
Friday, 12 Jul 2019 

July 12 (Reuters) - Genmab A/S ::GENMAB ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO U.S. FDA FOR SUBCUTANEOUS FORMULATION OF DARATUMUMAB.GENMAB - ITS LICENSING PARTNER, JANSSEN BIOTECH, SUBMITTED BLA TO FDA FOR USE OF SUBQ FORMULATION OF DARATUMUMAB IN MULTIPLE MYELOMA INDICATIONS.  Full Article

Johnson & Johnson to undertake an investigational study for HIV Vaccine
Friday, 12 Jul 2019 

July 12 (Reuters) - Johnson & Johnson ::J&J - PHASE 3 EFFICACY STUDY FOR INVESTIGATIONAL JANSSEN PREVENTIVE HIV VACCINE PLANNED TO TAKE PLACE.J&J - CO'S STUDY FOR INVESTIGATIONAL HIV VACCINE PLANNED TO TAKE PLACE IN MULTIPLE COUNTRIES ACROSS NORTH AMERICA, SOUTH AMERICA, EUROPE.J&J, ON STUDY FOR INVESTIGATIONAL HIV VACCINE, SAYS IN PROCESS OF SUBMITTING REGULATORY APPLICATIONS TO RESPECTIVE HEALTH AUTHORITIES.  Full Article

Vaxart Enters Into Research Collaboration With Janssen To Evaluate Oral Universal Influenza Vaccine
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Vaxart Inc ::VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO EVALUATE ORAL UNIVERSAL INFLUENZA VACCINE.VAXART INC - ORAL UNIVERSAL FLU VACCINE CANDIDATE TO BE EVALUATED IN PRE-CLINICAL CHALLENGE MODEL.VAXART INC - VAXART WILL PRODUCE AN ORAL VACCINE CONTAINING CERTAIN PROPRIETARY ANTIGENS FROM JANSSEN.VAXART INC - UPON COMPLETION OF STUDY JANSSEN WILL HAVE AN EXCLUSIVE OPTION TO NEGOTIATE AN EXCLUSIVE WORLDWIDE LICENSE TO VAXART TECHNOLOGY.  Full Article

Johnson & Johnson - Xarelto (Rivaroxaban) Helps Protect Pediatric Patients From Blood Clots In Late-Breaking Phase 3 Einstein-Jr Study
Monday, 8 Jul 2019 

July 8 (Reuters) - Johnson & Johnson ::XARELTO (RIVAROXABAN) HELPS PROTECT PEDIATRIC PATIENTS FROM BLOOD CLOTS IN LATE-BREAKING PHASE 3 EINSTEIN-JR STUDY.JANSSEN PHARMACEUTICAL COMPANIES - ANNOUNCED NEW RESULTS FROM PHASE 3 EINSTEIN-JR STUDY.JANSSEN PHARMACEUTICAL - RECURRENT VTE SIMILAR IN BOTH TREATMENT GROUPS, WITH NUMERICALLY LOWER NUMBER OF EVENTS IN PATIENTS TREATED WITH XARELTO.JANSSEN PHARMACEUTICAL - STUDY MET ALL OF ITS PRESPECIFIED ENDPOINTS.  Full Article

Tracon Pharmaceuticals Provides Update On Phase 1/2 Trial Of Trc253
Tuesday, 2 Jul 2019 

July 2 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS PROVIDES UPDATE ON PHASE 1/2 TRIAL OF TRC253 IN PATIENTS WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER.TRACON PHARMACEUTICALS INC - PHASE 1 DATA PUBLISHED IN ASCO PROCEEDINGS DETERMINED RECOMMENDED PHASE 2 DOSE.TRACON PHARMACEUTICALS INC - ADDITIONAL COHORT OF PATIENTS WITH A SPECIFIC ANDROGEN RECEPTOR POINT MUTATION ADDED TO ONGOING PHASE 2 STUDY.TRACON PHARMACEUTICALS INC - PHASE 2 DATA EXPECTED IN 2(ND) HALF 2020; POTENTIAL FOR $45 MILLION OPT-IN PAYMENT FROM JANSSEN.TRACON PHARMACEUTICALS INC - TRC253 WAS WELL-TOLERATED AND NO DRUG-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED.  Full Article

Janssen Pharmaceutical Companies Announced Today Results From Phase 3 Columba (MMY3012) Study
Sunday, 2 Jun 2019 

June 2 (Reuters) - :JANSSEN PHARMACEUTICAL COMPANIES- CO ANNOUNCED TODAY RESULTS FROM PHASE 3 COLUMBA (MMY3012) STUDY.JANSSEN PHARMACEUTICAL- RESULTS SHOWED NON-INFERIORITY TO INTRAVENOUS ADMINISTRATION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.JANSSEN- AT MEDIAN FOLLOW-UP OF 7.5 MONTHS, OVERALL RESPONSE RATE WAS 41% FOR SC ADMINISTERED FORMULATION OF DARZALEX COMPARED TO 37% FOR DARZALEX IV.  Full Article

Johnson & Johnson Says South Carolina Jury Clears It Of Liability In Lawsuit Alleging Asbestos In Talc Caused Woman's Cancer
Tuesday, 21 May 2019 

Johnson & Johnson ::JOHNSON & JOHNSON SAYS SOUTH CAROLINA JURY CLEARS IT OF LIABILITY IN LAWSUIT ALLEGING ASBESTOS IN TALC CAUSED WOMAN'S CANCER.  Full Article

Minerva Neurosciences Announces Positive Top Line Results In Phase 2B Clinical Trial With Seltorexant (Min-202)
Monday, 13 May 2019 

May 13 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES ANNOUNCES POSITIVE TOP LINE RESULTS IN PHASE 2B CLINICAL TRIAL WITH SELTOREXANT (MIN-202) IN TREATMENT OF DEPRESSED PATIENTS WITH AN INADEQUATE RESPONSE TO SSRIS AND SNRIS.MINERVA NEUROSCIENCES INC - SELTOREXANT WAS WELL TOLERATED, WITH ADVERSE EVENTS SIMILAR TO OR LOWER THAN RATE OBSERVED IN PLACEBO GROUP.MINERVA NEUROSCIENCES INC - SELTOREXANT DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT IN MADRS SCORES AT 6 WEEKS COMPARED TO PLACEBO.MINERVA NEUROSCIENCES INC - SELTOREXANT IMPROVES DEPRESSIVE SYMPTOMS AND SLEEP FUNCTION.MINERVA NEUROSCIENCES INC - SELTOREXANT DEMONSTRATES IMPROVEMENT IN SYMPTOMS OF MDD PATIENTS NOT ADEQUATELY TREATED BY SSRIS AND/OR SNRIS.MINERVA NEUROSCIENCES - TOP LINE RESULTS FROM SEPARATE PHASE 2B TRIAL OF SELTOREXANT IN INSOMNIA ARE EXPECTED TO BE ANNOUNCED LATER THIS QUARTER.  Full Article

J&J Says At Annual Meeting, Shareholders Did Not Approve Proposal For Clawback Disclosure
Friday, 26 Apr 2019 

April 26 (Reuters) - Johnson & Johnson ::J&J - AT THE ANNUAL MEETING OF THE SHAREHOLDERS, SHAREHOLDERS DID NOT APPROVE THE SHAREHOLDER PROPOSAL FOR CLAWBACK DISCLOSURE.J&J - AT THE ANNUAL MEETING, SHAREHOLDERS DID NOT APPROVE THE SHAREHOLDER PROPOSAL FOR EXECUTIVE COMPENSATION AND DRUG PRICING RISKS.J&J - AT THE ANNUAL MEETING OF THE SHAREHOLDERS, SHAREHOLDERS ELECTED ALL 12 DIRECTOR NOMINEES NAMED IN 2019 PROXY STATEMENT TO BOARD.  Full Article

Photo

Opioid 'kingpin' J&J fueled epidemic, Oklahoma argues at trial's end

NORMAN, Okla. Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson to a drug cartel leader as they sought to hold the drugmaker responsible for fueling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis.